Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $170 and keeps a Buy rating on the shares following a transfer of analyst coverage. The firm says that while further declines in Humira revenues are expected, it expects them to have minimal overall impact. AbbVie is now on a path for sustainable revenue growth of 4% to 9% for the next five years, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie, Gedeon Richter collaborate for discovery, development of novel targets
- Regenxbio presents positive Phase 2 data of ABBV-RGX-314 in wet AMD
- Allergan’s BOTOX Cosmetic gets FDA approval in jaw-neck bands
- AbbVie price target raised to $195 from $185 at BofA
- Uber downgraded, Zoom Video upgraded: Wall Street’s top analyst calls